Cover Image

Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients

BACKGROUND: The role of second-line chemotherapy in advanced gastric cancer is not yet fully established. - PATIENTS AND METHODS: We analysed 111 patients with advanced gastric cancer treated at the University Hospital Heidelberg (51) and the private oncology practice Bottrop/Dorsten (60) between 20...

Full description

Saved in:
Bibliographic Details
Main Authors: Elsing, Christoph (Author) , Herrmann, Christina (Author) , Hannig, Carla Verena (Author) , Stremmel, Wolfgang (Author) , Jäger, Dirk (Author) , Herrmann, Thomas (Author)
Format: Article (Journal)
Language:English
Published: October 29, 2013
In: Oncology
Year: 2013, Volume: 85, Issue: 5, Pages: 262-268
ISSN:1423-0232
DOI:10.1159/000355690
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000355690
Get full text
Author Notes:Christoph Elsing, Christina Herrmann, Carla Verena Hannig, Wolfgang Stremmel, Dirk Jäger, Thomas Herrmann
Description
Summary:BACKGROUND: The role of second-line chemotherapy in advanced gastric cancer is not yet fully established. - PATIENTS AND METHODS: We analysed 111 patients with advanced gastric cancer treated at the University Hospital Heidelberg (51) and the private oncology practice Bottrop/Dorsten (60) between 2001 and 2011, comparing the outcome of patients with first-line chemotherapy and those who received second-line chemotherapy. - RESULTS: Thirty-six patients were treated with one chemotherapy regimen, 75 patients received at least two different chemotherapies. Patients who received one chemotherapy regimen were older (median age 69 years) and had a shorter overall survival (6 months) than patients receiving sequential chemotherapies [median age 61 years, p = 0.009, overall survival 14 months (2-42), p = 0.001]. Under second-line chemotherapy, partial response was observed in 25 patients (33%) and stable disease for ≥3 months in 26 patients (35%). Patients treated before 2005 had a slightly better overall survival than patients treated in or after 2005. Survival was not influenced by the treatment centre (primary or tertiary), but was influenced by former surgery. - CONCLUSION: The prognosis of advanced gastric cancer is still poor. Selected patients may benefit from individualized salvage chemotherapy after failure of first-line chemotherapy.
Item Description:Gesehen am 05.02.2021
Physical Description:Online Resource
ISSN:1423-0232
DOI:10.1159/000355690

Similar Items